111 results on '"Bono P."'
Search Results
2. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer
3. LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types
4. 749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
5. 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer
6. SO-18 Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial
7. Stone related preoperative factors affecting postoperative PCNL Stone Free Rate (SFR)
8. Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours
9. Stone related preoperative factors affecting postoperative PCNL stone free rate (SFR)
10. Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours
11. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy
12. Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)
13. Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
14. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
15. Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact
16. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations
17. Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032
18. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma
19. PO-0624: Gammaknife Radiosurgery in patients receiving anticancer immunotherapy: efficacy and safety
20. EP-1127: Dose to hippocampus in brain metastases radiosurgery: need for an hippocampal sparing approach
21. Surgical correction of Peyronie’s disease via tunica albuginea plication - long term follow up
22. Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study
23. Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
24. Novel angiogenesis markers as long-term prognostic factors in renal cell cancer
25. Everolimus-induced pneumonitis as predictor of outcome in patients with metastatic renal cell carcinoma
26. Acute respiratory distress syndrome in adenovirus type 4 pneumonia: A case report
27. Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy
28. Association of angiopoietin-2 and Ki-67 expression with vascular density and sunitinib response in metastatic renal cell carcinoma
29. Role of flax cell wall components on the microstructure and transverse mechanical behaviour of flax fabrics reinforced epoxy biocomposites
30. 765 Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial
31. 1086 Thulium laser enucleation (thulep) versus transurethral resection of the prostate in saline (turis): A randomized prospective trial to compare intra and early postoperative outcomes
32. Gamma Knife Radiosurgery in the management of single and multiple brain metastases
33. Core Antigen Quantification to Monitor Treatment Efficacy in Patients with Chronic Hepatitis C Receiving Directly Acting Antivirals
34. Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies
35. 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
36. 442 VEGFR, CD, MIB-1 and Bcl-2 expressions as long-term prognostic factors in renal cell cancer
37. 433 Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma (mRCC)
38. 567 Safety and antitumor activity of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients from the ARADES and the ARAFOR trials
39. PO-0807: Radiosurgery and brain metastases: high-resolution MRI can significantly change intracranial disease staging
40. EP-1357: GammaKnife Radiosurgery in the management of single and multiple brain metastases
41. Hepatitis Delta prevalence and clinical expression in an immigrant population in Italy
42. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
43. Multi-scale study of the adhesion between flax fibers and biobased thermoset matrices
44. Radicular Somatosensory Evoked Potentials Recording During Foraminotomy
45. Uses for CGM in Raster-to-Vector Conversion
46. A Reference Model for Computer Graphics Standards
47. Correlation of Tumour C-Met Expression and Outcome in Patients with Renal Cell Carcinoma (Rcc) Treated with Sunitinib
48. O7.02 * RADIOSURGERY AND BRAIN METASTASES: ADEQUATE SEQUENCE OF BRAIN MRI CAN SIGNIFICANTLY CHANGE THE INTRACRANIAL DISEASE STAGING
49. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
50. 862 Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.